"You may not have your eye on Alcon Inc. (NYSE: ACL), but if you wear contact lenses, suffer from dry eyes, worry about glaucoma, or even if you have hay-fever, you may have bought ACL products," notes global expert Frida Ghitis.
Here, the contributing advisor to Vivian Lewis' Global Investing, explains, "This Swiss eye drug giant has with its eyes on both the bottom line and the pipeline.
"As the world's largest eye care company, ALC has excellent management, stellar performance, promising demographics, and an intriguing ownership structure.
"Demographics bode well. Aging eyes need attention. Demand will rise for glaucoma medication, dry eye treatments, and other Alcon top sellers. As emerging markets grow their middle class, eye-care will be affordable by millions more people.

What are the best speculations and investments among metals, miners, and other resource plays? To find out, I turned to 20 of the nation's leading newsletter editors, as well as speakers from the recent 







